dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Selmaj, Krzysztof W. |
dc.contributor.author | Cohen, Jeffrey A |
dc.contributor.author | Comi, Giancarlo |
dc.contributor.author | Arnold, Douglas L |
dc.contributor.author | Steinman, Lawrence |
dc.contributor.author | Montalban Gairín, Xavier |
dc.contributor.author | Bar-Or, Amit |
dc.date.accessioned | 2022-02-24T16:27:50Z |
dc.date.available | 2022-02-24T16:27:50Z |
dc.date.issued | 2021-06 |
dc.identifier.citation | Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, et al. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Mult Scler Relat Disord. 2021 Jun;51:102844. |
dc.identifier.issn | 2211-0348 |
dc.identifier.uri | https://hdl.handle.net/11351/7079 |
dc.description | Esdeveniments adversos; Esclerosi múltiple; Ozanimod |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Multiple Sclerosis and Related Disorders;51 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Multiple Sclerosis, Relapsing-Remitting |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Treatment Outcome |
dc.title | Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.msard.2021.102844 |
dc.subject.decs | esclerosis múltiple recurrente-remitente |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1016/j.msard.2021.102844 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Selmaj KW] Center for Neurology, 90-324 Łódź, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, 11-082 Olsztyn, Poland. [Cohen JA] Department of Neurology, Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA. [Comi G] Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, 20132 Milan, Italy. [Bar-Or A] Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA. [Arnold DL] NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, Quebec, H3A 2B4, Canada. [Steinman L] Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California 94305, USA. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 33892317 |
dc.identifier.wos | 000689354300026 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |